ArticleFrontiers in pharmacology2022
Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 38 citations in OpenAlex.
- Edible Fungi and Skin Redox Homeostasis: Bioactive Diversity, Processing, Oral Exposure, and Evidence Gaps.Antioxidants (Basel, Switzerland) · 2026Review
- Six Bioactive Small Molecules fromFoods (Basel, Switzerland) · 2026Article
- Application of Metabolomics in the Exploration of Bioactive Compounds and Drug Development from Medicinal Fungi.Metabolites · 2026Review
- Article
- Article
- Impact of Antioxidant-Rich Whole Foods or Supplements on Skin Health: A Systematic Review and Meta-Analysis of Preclinical and Clinical Studies.Antioxidants (Basel, Switzerland) · 2026Review
- Engineering Multi-Scale Transdermal Delivery Systems for Atopic Dermatitis: Emerging Insights from the Gut-Skin Axis.International journal of nanomedicine · 2026Review
- Application of edible fungi in gut microbiota regulation.NPJ science of food · 2025Review
- Oral Prescription Containing Ceramide, Proanthocyanidins, Quercetin, and Citrus Flavonoids Improves Sensitive Skin in Mice by Modulating Inflammation, Skin Barrier Function, and Gut Microbiota.Journal of cosmetic dermatology · 2025Article
- Analysis of Microbial Community Structure and Cultivation Performance Assessment inJournal of fungi (Basel, Switzerland) · 2025Article
- Anti-Stress Effects ofNutrients · 2025Article
- Recent advances in polysaccharides fromFrontiers in nutrition · 2025Review
- Article
- Comparative transcriptome analyses and CRISPR/Cas9-mediated functional study ofFrontiers in microbiology · 2025Article
- Article
- Macrofungal Extracts as a Source of Bioactive Compounds for Cosmetical Anti-Aging Therapy: A Comprehensive Review.Nutrients · 2024Review
- The potential cutaneous benefits of Tremella fuciformis.Archives of dermatological research · 2023Review
- A review of the auditory-gut-brain axis.Frontiers in neuroscience · 2023Review
- Anti-inflammatory and immunomodulatory effects of polysaccharide extracted from Wuguchong (maggot) on 2,4-dinitrochlorobenzene-induced atopic dermatitis in mice.Frontiers in pharmacology · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atopic dermatitis (AD), characterized by severe pruritus, immune imbalance, and skin barrier dysfunction, has a high incidence worldwide. Recent evidence has shown that the modulation of gut microbiota is crucial for alleviating clinical symptoms of AD. Tremella fuciformis polysaccharides (TFPS) have been demonstrated to have a variety of biological activities such as immunomodulatory, anti-tumor, antioxidant, anti-inflammatory, neuroprotective, hypoglycemic and hypolipidemic effects. However, their effects on AD treatment have never been investigated. In this study, we compared the therapeutic effects of topical or oral administration of TFPS on AD in dinitrofluorobenzene (DNFB)-induced AD mice. Both topical application and oral administration of TFPS led to improvement on transdermal water loss, epidermal thickening, and ear edema in AD mice, but the oral administration showed significantly better efficacy than the topical application. The TFPS treatment increased the proportion of CD4 (+) CD25 (+) Foxp3 (+) regulatory T cells in mesenteric lymph nodes. Additionally, the non-targeted metabolomics and sequencing of 16S rDNA amplicons were performed, revealing metabolite modulation in feces and changed composition of gut microbiota in mice, which were induced for AD-like disorder and treated by oral administration of TFPS. Collectively, these data suggest that the oral administration of TFPS may constitute a novel effective therapy for AD, with underlying mechanisms associated with the regulation of immune response, and improvement of both metabolism and the composition of intestinal microbiota.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.